PARIS--(BUSINESS WIRE)--Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.
ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.
ReCor Medical is an innovative medical device company that developed the Paradise® System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.
Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”
Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”
Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”
Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.
About Sofinnova Partners
Sofinnova Partners is a
leading European venture capital firm specialized in Life Sciences.
Based in Paris, France, the firm brings together a team of professionals
from all over Europe, the US and China. The firm focuses on paradigm
shifting technologies alongside visionary entrepreneurs. Sofinnova
Partners seeks to invest as a lead or cornerstone investor in seed,
start-ups, corporate spin-offs and late stage companies. It has backed
nearly 500 companies over more than 45 years, creating market leaders
around the globe. Today, Sofinnova Partners has over €1.9 billion under
management. For more information: www.sofinnova.fr
About ReCor Medical, Inc.
ReCor Medical is a
medical device company that designs and manufactures the Paradise
System, a proprietary ultrasound ablation system for renal denervation
(RDN). RDN is a new potential therapeutic approach for the treatment of
hypertension, one of the most prevalent medical conditions. The Paradise
System is approved for sale in the EU and bears a CE mark, but is not
approved for sale in the United States. The System's intravascular
catheters denervate renal nerves by combining the protection of
water-based cooling of the renal artery with high intensity ultrasound
energy for circumferential renal nerve ablation. The Paradise System has
been studied in clinical trials of approximately 300 patients to date.
Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor
will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a
feasibility study of patients with resistant hypertension) and REQUIRE
(a pivotal study of patients with resistant hypertension in Japan and
Korea), and launch the RADIANCE II pivotal study (a study of patients
with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/
About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co.,
Ltd.
Otsuka Holdings Co., Ltd. is the holding company of
the Otsuka group, a global healthcare group headquartered in Tokyo,
Japan. With operations in pharmaceuticals, nutraceuticals, medical
devices and other health-related businesses, the group generated
worldwide sales of JPY1,240 billion in the fiscal year ended December
2017.
http://www.otsuka.com/en/
Established in 2011, Otsuka Medical Devices Co., Ltd. is a
fully-owned subsidiary of Otsuka Holdings and one of its core operating
subsidiaries. Otsuka Medical Devices focuses on the development and
commercialization of endovascular devices that provide new therapeutic
options in areas where patient needs cannot be met through
pharmaceutical or other conventional treatment.
Otsuka
Medical Devices conducts the REQUIRE trial for renal denervation in
hypertensive patients (n=140), who are uncontrolled on 3 or more
medications including a diuretic, in Japan and Korea through its
subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/
